{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:06:26Z","timestamp":1790802386871,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejca.2026.117047","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:47:40Z","timestamp":1789195660000},"page":"117047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dual checkpoint blockade beyond clinical trials: Real-world experience with nivolumab-relatlimab in advanced melanoma"],"prefix":"10.1016","volume":"247","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4094-8045","authenticated-orcid":false,"given":"Nethanel","family":"Asher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moti","family":"Avner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2146-5072","authenticated-orcid":false,"given":"Nadav","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gal","family":"Markel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Israei-Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1618-1575","authenticated-orcid":false,"given":"Rami","family":"Dokhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaked","family":"Lev-Ari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0562-2100","authenticated-orcid":false,"given":"Shirly","family":"Grynberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Bar-Sela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehud","family":"Wainstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Yakobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mor","family":"Miodovnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ela","family":"Kozlener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi F.","family":"Rasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Lotem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.117047_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcskn.2025.100285","article-title":"Selecting first-line immunotherapy in advanced melanoma: current evidence on efficacy across diverse patient populations","volume":"3","author":"Kreft","year":"2025","journal-title":"EJC Skin Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2026.117047_bib2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2026.117047_bib3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117047_bib4","unstructured":"Rendon A., Rayi A.Nivolumab StatPearls. Publishing StatPearls; 2025. [Accessed January 30, 2026]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK567801\/."},{"issue":"9","key":"10.1016\/j.ejca.2026.117047_bib5","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.3390\/cancers13092112","article-title":"LAG-3 blockade with relatlimab (BMS-986016) restores anti-leukemic responses in chronic lymphocytic leukemia","volume":"13","author":"Sordo-Bahamonde","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.ejca.2026.117047_bib6","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1158\/2326-6066.CIR-22-0057","article-title":"Preclinical characterization of relatlimab, a human LAG-3-blocking antibody, alone or in combination with nivolumab","volume":"10","author":"Thudium","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"15","key":"10.1016\/j.ejca.2026.117047_bib7","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1200\/JCO.22.02072","article-title":"Nivolumab and relatlimab in patients with advanced melanoma that had progressed on anti-programmed death-1\/programmed death ligand 1 therapy: results from the phase I\/IIa RELATIVITY-020 Trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.117047_bib8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117047_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115547","article-title":"Nivolumab plus relatlimab in advanced melanoma: relativity-047 4-year update","volume":"225","author":"Lipson","year":"2025","journal-title":"Eur J Cancer"},{"issue":"14","key":"10.1016\/j.ejca.2026.117047_bib10","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2026.117047_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2026.117047_bib12","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.3390\/cancers12082329","article-title":"Real world outcomes of ipilimumab and nivolumab in patients with metastatic melanoma","volume":"12","author":"Asher","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2026.117047_bib13","unstructured":"Research C for DE and. FDA approves Opdualag for unresectable or metastatic melanoma. FDA. Published online2022https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-opdualag-unresectable-or-metastatic-melanoma."},{"key":"10.1016\/j.ejca.2026.117047_bib14","unstructured":"Opdualag Approved to Treat Advanced Melanoma - NCI2022. Accessed January 30, 2026. https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2022\/fda-opdualag-melanoma-lag-3."},{"key":"10.1016\/j.ejca.2026.117047_bib15","unstructured":"Opdualag | European Medicines Agency (EMA)2022. Accessed January 30, 2026. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/opdualag."},{"key":"10.1016\/j.ejca.2026.117047_bib16","unstructured":"\u05d4\u05e8\u05d7\u05d1\u05ea \u05e1\u05dc \u05e9\u05d9\u05e8\u05d5\u05ea\u05d9 \u05d4\u05d1\u05e8\u05d9\u05d0\u05d5\u05ea \u05dc\u05e9\u05e0\u05ea 2023. www.gov.il.2026. https:\/\/www.gov.il\/he\/pages\/mtr01-2023."},{"issue":"8","key":"10.1016\/j.ejca.2026.117047_bib17","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.3390\/cancers12082329","article-title":"Real world outcomes of ipilimumab and nivolumab in patients with metastatic melanoma","volume":"12","author":"Asher","year":"2020","journal-title":"Cancers"},{"issue":"33","key":"10.1016\/j.ejca.2026.117047_bib18","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1200\/JCO.24.01125","article-title":"First-line nivolumab plus relatlimab versus nivolumab plus ipilimumab in advanced melanoma: an indirect treatment comparison using relativity-047 and checkmate 067 trial data","volume":"42","author":"Long","year":"2024","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2026.117047_bib19","doi-asserted-by":"crossref","first-page":"9527","DOI":"10.1200\/JCO.2025.43.16_suppl.9527","article-title":"Real-world comparison of survival with nivolumab (NIVO) + relatlimab (RELA) vs NIVO + ipilimumab (IPI) in advanced melanoma","volume":"43","author":"Postow","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117047_bib20","doi-asserted-by":"crossref","first-page":"S731","DOI":"10.1016\/j.annonc.2024.08.1171","article-title":"1103P Real-world efficacy of relatlimab and nivolumab in advanced or resectable melanoma","volume":"35","author":"Karapetyan","year":"2024","journal-title":"Ann Oncol"},{"issue":"16_","key":"10.1016\/j.ejca.2026.117047_bib21","article-title":"Real-world treatment patterns and outcomes of patients with advanced melanoma treated with nivolumab plus relatimab","volume":"42","author":"Thakker","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_","key":"10.1016\/j.ejca.2026.117047_bib22","article-title":"Real-world outcomes in patients with brain metastases secondary to melanoma treated with nivolumab\/relatlimab","volume":"43","author":"Yamazawa","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.117047_bib23","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1470-2045(24)00735-6","article-title":"Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study","volume":"26","author":"Long","year":"2025","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2026.117047_bib24","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117047_bib25","article-title":"Real world comparison of immune-related adverse events with nivolumab-relatlimab versus ipilimumab-nivolumab in patients with advanced cutaneous melanoma","author":"Kielkowski","year":"2024","journal-title":"J Oncol Pharm Pract Publ Int Soc Oncol Pharm Pract"},{"key":"10.1016\/j.ejca.2026.117047_bib26","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1186\/s12885-025-14546-6","article-title":"Comparative safety of nivolumab plus ipilimumab versus nivolumab plus relatlimab in advanced melanoma: a pharmacovigilance study based on the FDA adverse event reporting system (FAERS)","volume":"25","author":"Xu","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2026.117047_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177991","article-title":"Safety profile of nivolumab-relatlimab in cancer patients: a living pharmacovigilance study of clinical trials and postmarketing data (version 1.0)","volume":"1004","author":"Zhu","year":"2025","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"10.1016\/j.ejca.2026.117047_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012225","article-title":"International real-world study of combination immunotherapy sequences in metastatic melanoma","volume":"13","author":"Guardamagna","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.117047_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcskn.2025.100285","article-title":"Selecting first-line immunotherapy in advanced melanoma: current evidence on efficacy across diverse patient populations","volume":"3","author":"Kreft","year":"2025","journal-title":"EJC Skin Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:34:27Z","timestamp":1790800467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926008282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":29,"alternative-id":["S0959804926008282"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117047","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual checkpoint blockade beyond clinical trials: Real-world experience with nivolumab-relatlimab in advanced melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117047"}}